References

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

10.1016/j.jhep.2019.03.013 · 2019 · External reference

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

10.1038/s41575-020-0310-z · 2020 · External reference

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

10.1053/j.gastro.2011.12.005 · 2012 · External reference

Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma

10.1097/sla.0000000000003801 · 2021 · External reference

Recommendations on Perihilar Cholangiocarcinoma. The Milan Jury-Based Consensus

10.1097/sla.0000000000006773 · 2025 · External reference

10.3322/caac.21388

10.3322/caac.21388 · External reference

Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma

10.1038/s41467-022-29164-0 · 2022 · External reference

Integrative analyses of bulk and single-cell transcriptomics reveals the infiltration and crosstalk of cancer-associated fibroblasts as a novel predictor for prognosis and microenvironment remodeling in intrahepatic cholangiocarcinoma

10.1186/s12967-024-05238-z · 2024 · External reference

Progression of Metastasis through Lymphatic System

10.3390/cells10030627 · 2021 · External reference

From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity

10.1038/nrd4608 · 2015 · External reference

Emerging Biological Principles of Metastasis

10.1016/j.cell.2016.11.037 · 2017 · External reference

Prediction of the lymph node status in patients with intrahepatic cholangiocarcinoma: analysis of 320 surgical cases

10.3389/fonc.2011.00042 · 2011 · External reference

Development and validation of a novel preoperative clinical model for predicting lymph node metastasis in perihilar cholangiocarcinoma

10.1186/s12885-024-12068-1 · 2024 · External reference

Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas

10.1245/s10434-008-0236-0 · 2009 · External reference

BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways

10.1038/s41419-018-1087-7 · 2018 · External reference

Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma

10.1016/j.ejca.2012.12.015 · 2013 · External reference

Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma

10.1002/hep.20718 · 2005 · External reference

Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha

10.2353/ajpath.2009.080012 · 2009 · External reference

MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways

10.1016/j.jhep.2019.11.021 · 2020 · External reference

Cancer metastases: challenges and opportunities

10.1016/j.apsb.2015.07.005 · 2015 · External reference

TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma

10.1186/s40659-015-0016-9 · 2015 · External reference

Inactivation of Smad4 is a prognostic factor in intrahepatic cholangiocarcinoma

10.3760/cma.j.issn.0366-6999.20121235 · 2013 · External reference

Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma

10.1038/s41419-017-0015-6 · 2017 · External reference

Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition

10.1002/hep.28149 · 2015 · External reference

Serine/threonine kinase TBK1 promotes cholangiocarcinoma progression via direct regulation of β-catenin

10.1038/s41388-023-02651-4 · 2023 · External reference

MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma

10.1016/j.dld.2018.08.021 · 2019 · External reference

WDHD1 modulates the post-transcriptional step of the centromeric silencing pathway

10.1093/nar/gkq1338 · 2011 · External reference

Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma

10.1016/j.jhep.2018.12.004 · 2019 · External reference

Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma

10.1016/j.jhep.2021.07.016 · 2021 · External reference

Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma

10.1038/ajg.2009.674 · 2010 · External reference

Tumor-associated lymphangiogenesis correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma

10.1245/s10434-007-9774-0 · 2008 · External reference

The biology of vascular endothelial growth factors

10.1016/j.cardiores.2004.12.002 · 2005 · External reference

Expression of VEGFR-3 in intrahepatic cholangiocarcinoma correlates with unfavorable prognosis through lymphangiogenesis

10.7150/ijbs.26045 · 2018 · External reference

Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma

10.1007/s00535-023-02012-8 · 2023 · External reference

High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery

10.1002/cncr.27788 · 2013 · External reference

Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma

10.1038/modpathol.3800985 · 2008 · External reference

Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks

10.1016/j.jhep.2016.09.010 · 2017 · External reference

Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells

10.1002/hep.24588 · 2011 · External reference

Cancer-Associated Fibroblasts Promote Lymphatic Metastasis in Cholangiocarcinoma via the PDGF-BB/PDGFR-β Mediated Paracrine Signaling Network

10.14336/ad.2023.0420 · 2024 · External reference

Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma

10.1002/hep.26384 · 2013 · External reference

Targeted amplicon sequencing for primary tumors and matched lymph node metastases in patients with extrahepatic cholangiocarcinoma

10.1016/j.hpb.2021.11.008 · 2022 · External reference

ACGH detects distinct genomic alterations of primary intrahepatic cholangiocarcinomas and matched lymph node metastases and identifies a poor prognosis subclass

10.1038/s41598-018-28941-6 · 2018 · External reference

Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma

10.1016/j.ccell.2021.12.006 · 2022 · External reference

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

10.1038/nature13441 · 2014 · External reference

KIF14 promotes proliferation, lymphatic metastasis and chemoresistance through G3BP1/YBX1 mediated NF-κB pathway in cholangiocarcinoma

10.1038/s41388-023-02661-2 · 2023 · External reference

UCP2 regulates cholangiocarcinoma cell plasticity via mitochondria-to-AMPK signals

10.1016/j.bcp.2019.05.017 · 2019 · External reference

Deconvoluting the context-dependent role for autophagy in cancer

10.1038/nrc3262 · 2012 · External reference

Prognostic significance of Beclin 1 in intrahepatic cholangiocellular carcinoma

10.4161/auto.7.10.16610 · 2011 · External reference

Beclin 1 deficiency correlated with lymph node metastasis, predicts a distinct outcome in intrahepatic and extrahepatic cholangiocarcinoma

2013 · External reference

Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma

10.4161/auto.6.3.11303 · 2010 · External reference

Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms

10.1158/2159-8290.cd-17-0952 · 2018 · External reference

Oleic acid-PPARγ-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment

10.1097/hep.0000000000000784 · 2024 · External reference

The metabolism of cancer cells during metastasis

10.1038/s41568-020-00320-2 · 2021 · External reference

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

10.1016/j.ccell.2023.02.016 · 2023 · External reference

Macrophage diversity enhances tumor progression and metastasis

10.1016/j.cell.2010.03.014 · 2010 · External reference

Biological functions of lymphatic vessels

10.1126/science.aax4063 · 2020 · External reference

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

10.1016/j.cell.2015.08.016 · 2015 · External reference

Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations

10.1016/j.ccell.2021.03.012 · 2021 · External reference

Hallmarks of cancer: the next generation

10.1016/j.cell.2011.02.013 · 2011 · External reference

Cholangiocarcinoma - novel biological insights and therapeutic strategies

10.1038/s41571-023-00770-1 · 2023 · External reference

Immunobiology of cholangiocarcinoma

10.1016/j.jhep.2023.05.010 · 2023 · External reference

Tumor microenvironment: Sanctuary of the devil

10.1016/j.canlet.2015.07.039 · 2015 · External reference

Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: A study based on single-cell and spatial transcriptomic sequencing

10.1097/hep.0000000000001423 · 2026 · External reference

Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer

10.1038/bjc.2013.610 · 2013 · External reference

High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy

10.1016/j.radonc.2015.07.003 · 2015 · External reference

Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy

10.3390/cells12060851 · 2023 · External reference

Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma

10.1002/cac2.12513 · 2024 · External reference

Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma

10.1016/j.jhep.2020.05.039 · 2020 · External reference

Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes

10.1038/s41379-020-00702-9 · 2021 · External reference

Macrophages-aPKCɩ-CCL5 Feedback Loop Modulates the Progression and Chemoresistance in Cholangiocarcinoma

10.1186/s13046-021-02235-8 · 2022 · External reference

What are regulatory T cells (Treg) regulating in cancer and why?

10.1016/j.semcancer.2012.03.004 · 2012 · External reference

Intratumoral IL-17+ cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma

10.1245/s10434-012-2268-8 · 2012 · External reference

aPKC-ι/P-Sp1/Snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma

10.1002/hep.29296 · 2017 · External reference

Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma

10.1038/s41416-021-01569-6 · 2022 · External reference

Alpha5 nicotine acetylcholine receptor subunit promotes intrahepatic cholangiocarcinoma metastasis

10.1038/s41392-024-01761-z · 2024 · External reference

Nerve growth factor-beta expression is associated with lymph node metastasis and nerve infiltration in human hilar cholangiocarcinoma

10.1007/s00268-010-0417-4 · 2010 · External reference

Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis

10.1038/s41416-022-01933-0 · 2022 · External reference

Spatial resolved transcriptomics reveals distinct cross-talk between cancer cells and tumor-associated macrophages in intrahepatic cholangiocarcinoma

10.1186/s40364-024-00648-z · 2024 · External reference

The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery

10.1002/cncr.34552 · 2023 · External reference

Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma

10.1245/s10434-016-5101-y · 2016 · External reference

Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma

10.1016/j.jhep.2021.10.030 · 2022 · External reference

Lymphangiogenesis requires Ang2/Tie/PI3K signaling for VEGFR3 cell-surface expression

10.1172/jci155478 · 2022 · External reference

The favorable prognosis after operative resection of hypervascular intrahepatic cholangiocarcinoma: A clinicopathologic and immunohistochemical study

10.1016/j.surg.2016.03.020 · 2016 · External reference

Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma

10.1053/j.gastro.2023.11.302 · 2024 · External reference

A CXCL1 paracrine network links cancer chemoresistance and metastasis

10.1016/j.cell.2012.04.042 · 2012 · External reference

Tumor Lymphatic Interactions Induce CXCR2-CXCL5 Axis and Alter Cellular Metabolism and Lymphangiogenic Pathways to Promote Cholangiocarcinoma

10.3390/cells10113093 · 2021 · External reference

Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma

10.1097/hep.0000000000000206 · 2024 · External reference

Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma

10.2353/ajpath.2006.050204 · 2006 · External reference

Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway

10.1186/s13046-014-0103-8 · 2014 · External reference

NF-κB, inflammation, immunity and cancer: coming of age

10.1038/nri.2017.142 · 2018 · External reference

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

10.1016/j.cmet.2016.08.011 · 2016 · External reference

Dangerous dynamic duo: Lactic acid and PD-1 blockade

10.1016/j.ccell.2022.01.008 · 2022 · External reference

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation

10.3389/fimmu.2021.636568 · 2021 · External reference

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer

10.1158/1078-0432.ccr-18-3200 · 2019 · External reference

Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma

10.1172/jci137110 · 2020 · External reference

Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors

10.1016/j.ccell.2017.10.005 · 2017 · External reference

Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis

10.1097/sla.0000000000003788 · 2021 · External reference

Circulating tumor DNA and liquid biopsy in oncology

10.1038/s43018-020-0043-5 · 2020 · External reference

Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma

10.1038/srep16103 · 2015 · External reference

Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma

10.1111/j.1478-3231.2004.00886.x · 2004 · External reference

Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma

10.1016/j.jhep.2021.06.028 · 2021 · External reference

Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment

10.1186/s13045-019-0772-z · 2019 · External reference

Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming

10.1016/j.cmet.2021.09.002 · 2021 · External reference

Circulating tumor cell-derived exosome-transmitted long non-coding RNA TTN-AS1 can promote the proliferation and migration of cholangiocarcinoma cells

10.1186/s12951-024-02459-8 · 2024 · External reference

LncRNA MT1JP plays a protective role in intrahepatic cholangiocarcinoma by regulating miR-18a-5p/FBP1 axis

10.1186/s12885-021-07838-0 · 2021 · External reference

Serum Angiopoietin-Like Protein 4: A Potential Prognostic Biomarker for Prediction of Vascular Invasion and Lymph Node Metastasis in Cholangiocarcinoma Patients

10.3389/fpubh.2022.836985 · 2022 · External reference

Integrin β6 serves as an immunohistochemical marker for lymph node metastasis and promotes cell invasiveness in cholangiocarcinoma

2016 · External reference

Integrin αvβ6 predicts poor prognosis and promotes resistance to cisplatin in hilar cholangiocarcinoma

10.1016/j.prp.2020.153022 · 2020 · External reference

Clinicopathological, etiological and molecular characteristics of intrahepatic cholangiocarcinoma subtypes classified by mucin production and immunohistochemical features

10.1080/14737159.2023.2205588 · 2023 · External reference

Intrahepatic, peri-hilar and distal cholangiocarcinoma: Three different locations of the same tumor or three different tumors?

10.1016/j.ejso.2015.05.013 · 2015 · External reference

Anatomic subsets of cholangiocarcinoma: More different than alike

10.1097/hep.0000000000001672 · 2026 · External reference

Understanding cholangiocarcinoma: molecular landscape, pathological classification, and challenges in biopsy diagnosis

10.1111/his.70157 · 2026 · External reference

Blurring the Anatomical Lines in Extrahepatic Cholangiocarcinoma: An Integrated Clinic-Oncological and Exploratory Proteomic Comparison of Perihilar and Distal Tumors

10.1245/s10434-025-17811-x · 2025 · External reference

Mobilization and activation of tumor-infiltrating dendritic cells inhibits lymph node metastasis in intrahepatic cholangiocarcinoma

10.1038/s41420-024-02079-z · 2024 · External reference

Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma

10.1038/s41416-022-01838-y · 2022 · External reference

Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma

10.1371/journal.pone.0081347 · 2013 · External reference

Dickkopf-1 expression is associated with tumorigenity and lymphatic metastasis in human hilar cholangiocarcinoma

10.18632/oncotarget.11859 · 2016 · External reference

Deciphering cholangiocarcinoma heterogeneity and specific progenitor cell niche of extrahepatic cholangiocarcinoma at single-cell resolution

10.1186/s13045-025-01716-z · 2025 · External reference

Activated cancer-associated fibroblasts correlate with poor survival and decreased lymphocyte infiltration in infiltrative type distal cholangiocarcinoma

10.1038/s41598-025-05645-2 · 2025 · External reference

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

10.1056/nejmoa0908721 · 2010 · External reference

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study

10.1016/j.jhep.2025.05.003 · 2025 · External reference

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s0140-6736(23)00727-4 · 2023 · External reference

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer

10.1158/1078-0432.ccr-24-0517 · 2024 · External reference

Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-arm, phase II study

2026 · External reference

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma

10.1056/nejmoa2513918 · 2026 · External reference

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

10.1136/jitc-2020-001240 · 2020 · External reference

A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC

10.1200/jco.2023.41.16_suppl.4015 · 2023 · External reference

Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review

2023 · External reference

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

10.1038/s41392-023-01317-7 · 2023 · External reference

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

10.1016/s2468-1253(24)00095-5 · 2024 · External reference

Envafolimab (KN035) plus gemcitabine and oxaliplatin (GEMOX) compared with GEMOX as first-line treatment for Chinese patients with advanced biliary tract cancer: A randomized, open-label, multi-center, phase III pivotal trial

10.1200/jco.2026.44.16_suppl.4118 · 2026 · External reference

First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer: A Systematic Review and Bayesian Network Meta-Analysis

10.1001/jamanetworkopen.2026.6849 · 2026 · External reference

CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis

10.6004/jnccn.2025.7384 · 2026 · External reference

Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A multicenter, single-arm, open-label, phase II study (ENLIGHTEN study)

2026 · External reference

Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma

10.1186/s40425-019-0501-8 · 2019 · External reference

Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

10.1186/s13045-016-0378-7 · 2017 · External reference

Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma

10.3389/fimmu.2023.1142690 · 2023 · External reference

Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis

10.1200/jco.2011.40.5381 · 2012 · External reference

Phase 2 Trial of Adjuvant Chemotherapy With S - 1 for Node-Positive Biliary Tract Cancer (N-SOG 09)

10.1245/s10434-020-08355-3 · 2020 · External reference

Adjuvant Chemoradiation in Patients with Lymph Node-Positive Biliary Tract Cancers: Secondary Analysis of a Single-Arm Clinical Trial (SWOG 0809)

10.1245/s10434-022-12863-9 · 2023 · External reference

Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma

10.1186/s12916-024-03381-4 · 2024 · External reference

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma

10.1371/journal.pgen.1004135 · 2014 · External reference

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

10.1016/s1470-2045(20)30109-1 · 2020 · External reference

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial

10.1200/jco-26-00788 · 2026 · External reference

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

10.1056/nejmoa2206834 · 2023 · External reference

Emerging molecular therapeutic targets for cholangiocarcinoma

10.1016/j.jhep.2017.03.026 · 2017 · External reference

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

10.1016/s1470-2045(20)30157-1 · 2020 · External reference

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

10.1016/s1470-2045(21)00336-3 · 2021 · External reference

Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01

10.1001/jamaoncol.2025.4736 · 2026 · External reference

Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial

10.1200/jco.23.02010 · 2024 · External reference

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

10.1016/s1470-2045(20)30321-1 · 2020 · External reference

Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial

10.1200/jco-25-03128 · 2026 · External reference

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer

10.1016/j.ejca.2025.115338 · 2025 · External reference

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

10.1016/s1470-2045(22)00541-1 · 2022 · External reference

Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy

10.1245/s10434-018-6392-y · 2018 · External reference

Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics

10.1007/s10555-006-9026-y · 2006 · External reference

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

10.1016/s1470-2045(11)70301-1 · 2012 · External reference

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

10.1016/s1470-2045(15)00139-4 · 2015 · External reference

The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial

10.1038/s41467-026-72541-2 · 2026 · External reference

Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma

10.1158/0008-5472.can-12-2130 · 2013 · External reference

A phase 1b/2 study of AK130 (TIGIT/TGF-β bispecific fusion protein) combined with ivonescimab in advanced biliary tract cancer (BTC)

2026 · External reference

CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis

10.1002/jso.25192 · 2018 · External reference

Silencing of CXCR4 inhibits tumor cell proliferation and neural invasion in human hilar cholangiocarcinoma

10.5009/gnl.2014.8.2.196 · 2014 · External reference

Dicer promotes tumorigenesis by translocating to nucleus to promote SFRP1 promoter methylation in cholangiocarcinoma cells

10.1038/cddis.2017.57 · 2017 · External reference

Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis

10.1245/s10434-013-3135-y · 2013 · External reference

COUP-TFII promotes metastasis and epithelial-to-mesenchymal transition through upregulating Snail in human intrahepatic cholangiocarcinoma

10.1093/abbs/gmaa117 · 2020 · External reference

Forkhead box protein C2 contributes to invasion and metastasis of extrahepatic cholangiocarcinoma, resulting in a poor prognosis

10.1111/cas.12249 · 2013 · External reference

MicroRNA-101 inhibits the migration and invasion of intrahepatic cholangiocarcinoma cells via direct suppression of vascular endothelial growth factor-C

10.3892/mmr.2015.4239 · 2015 · External reference

MiR-19b-3p facilitates the proliferation and epithelial-mesenchymal transition, and inhibits the apoptosis of intrahepatic cholangiocarcinoma by suppressing coiled-coil domain containing 6

10.1016/j.abb.2020.108367 · 2020 · External reference

miR-204 inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells

10.1159/000354531 · 2013 · External reference

miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma

10.1002/mc.23262 · 2020 · External reference

miR-181b-5p Promotes the Progression of Cholangiocarcinoma by Targeting PARK2 via PTEN/PI3K/AKT Signaling Pathway

10.1007/s10528-021-10084-5 · 2022 · External reference

Up-regulated LINC00261 predicts a poor prognosis and promotes a metastasis by EMT process in cholangiocarcinoma

10.1016/j.prp.2019.152733 · 2020 · External reference

JUND/linc00976 promotes cholangiocarcinoma progression and metastasis, inhibits ferroptosis by regulating the miR-3202/GPX4 axis

10.1038/s41419-022-05412-5 · 2022 · External reference

Long Non-coding RNA FOXD2-AS1 Promotes Proliferation, Migration, and Invasion in Cholangiocarcinoma Through Regulating miR-760/E2F3 Axis

10.1007/s10620-021-06876-9 · 2022 · External reference

LncRNA NEAT1 promotes cell proliferation, migration, and invasion via the miR-186-5p/PTP4A1 axis in cholangiocarcinoma

10.1002/kjm2.12354 · 2021 · External reference

Yin Yang 1-induced LINC00667 up-regulates pyruvate dehydrogenase kinase 1 to promote proliferation, migration and invasion of cholangiocarcinoma cells by sponging miR-200c-3p

10.1007/s13577-020-00448-1 · 2021 · External reference

VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization

10.1007/s00535-023-02015-5 · 2023 · External reference

Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma

10.1007/s00535-024-02090-2 · 2024 · External reference

Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma

10.1080/19490976.2022.2156255 · 2023 · External reference

FomA-Containing Outer Membrane Vesicles of Fusobacterium Nucleatum Facilitate Bladder Cancer Lymphatic Metastasis via IL-6-Dependent M2b Macrophage Polarization

2026 · External reference

A pan-cancer analysis of the microbiome in metastatic cancer

10.1016/j.cell.2024.03.021 · 2024 · External reference

Unveiling the intratumor microbiome in liver cancer: Current insights and prospective applications

10.3350/cmh.2024.1039 · 2025 · External reference

67 laminin receptor promotes the malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma

10.1016/j.dld.2014.03.017 · 2014 · External reference

Serum Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) Level as a Potential Biomarker of Cholangiocarcinoma

10.3390/biom9090413 · 2019 · External reference

Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type

10.1097/pas.0b013e31820ffdf1 · 2011 · External reference

Apoptosis-Inducing Factor, Mitochondrion-Associated 3 (AIFM3) Protein Level in the Sera as a Prognostic Marker of Cholangiocarcinoma Patients

10.3390/biom10071021 · 2020 · External reference

TPX2 level correlates with cholangiocarcinoma cell proliferation, apoptosis, and EMT

10.1016/j.biopha.2018.08.011 · 2018 · External reference

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma

10.3389/fimmu.2021.705378 · 2021 · External reference

c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma

10.1046/j.1365-2559.2002.00353.x · 2002 · External reference

Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4)

10.1016/j.biopha.2021.112403 · 2022 · External reference

Calcium-sensing receptor promotes tumor proliferation and migration in human intrahepatic cholangiocarcinoma by targeting ERK signaling pathway

10.1016/j.ejphar.2020.172915 · 2020 · External reference

Expression of cytoskeleton-associated protein 4 is related to lymphatic metastasis and indicates prognosis of intrahepatic cholangiocarcinoma patients after surgery resection

10.1016/j.canlet.2013.05.003 · 2013 · External reference

TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-κB pathway-mediated inflammatory responses

10.1111/febs.13894 · 2016 · External reference

Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma

10.1097/01.mp.0000086860.65672.73 · 2003 · External reference

Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma

10.1002/cncr.10398 · 2002 · External reference

HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathway

10.1016/j.tranon.2025.102290 · 2025 · External reference

Impact of serum carbohydrate antigen 19-9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma

2018 · External reference